Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.

Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, Phung V, Guo G, Wang Y, Graham MP, Flynn S, Brenner JC, Li C, Villarroel MC, Schultz PG, Wu X, McNamara P, Sellers WR, Petruzzelli L, Boral AL, Seidel HM, McLaughlin ME, Che J, Carey TE, Vanasse G, Harris JL.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. doi: 10.1073/pnas.1314239110. Epub 2013 Nov 25.

2.

Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.

Villarroel MC, Pratz KW, Xu L, Wright JJ, Smith BD, Rudek MA.

Invest New Drugs. 2012 Dec;30(6):2096-102. doi: 10.1007/s10637-011-9767-5. Epub 2011 Nov 17.

3.

A Clinical Database-Driven Approach to Decision Support: Predicting Mortality Among Patients with Acute Kidney Injury.

Celi LA, Tang RJ, Villarroel MC, Davidzon GA, Lester WT, Chueh HC.

J Healthc Eng. 2011 Mar;2(1):97-110. Epub 2011 Apr 12.

4.

Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.

Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M.

Mol Cancer Ther. 2011 Jan;10(1):3-8. doi: 10.1158/1535-7163.MCT-10-0893. Epub 2010 Dec 6.

5.

Mycophenolate mofetil: An update.

Villarroel MC, Hidalgo M, Jimeno A.

Drugs Today (Barc). 2009 Jul;45(7):521-32. doi: 10.1358/dot.2009.45.7.1384878. Review.

PMID:
19834629

Supplemental Content

Loading ...
Support Center